Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
Strong Buy Rating for Poseida Therapeutics Amidst Strategic Partnerships and Robust CAR-T Manufacturing Capabilities
Strategic Advancements and Favorable Deal Terms Reinforce Buy Rating for Poseida Therapeutics
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
Poseida Therapeutics (PSTX) and Astellas Pharma subsidiary Xyphos Biosciences have entered into a research partnership and license agreement to develop new cancer cell therapy platforms using the Xyph
Express News | Astellas Pharma: Poseida Is Eligible for up to Low Double Digit Tiered Royalties as a Percentage of Net Sales
Express News | Astellas Pharma: Poseida Will Receive Contingency Payments of up to US $550 Million in Total
Express News | Astellas Pharma: Poseida Will Receive US $50 Million Upfront Plus Potential Development and Sales Milestones
Biotech Soars on Research Collaboration And License Agreement Release
Poseida Gains on Cell Therapy Pact With Astellas
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
By Chris Wack Poseida Therapeutics shares were up 18% to $2.86 after the company said it entered into a research collaboration and license agreement with Astellas Pharma's Xyphos Biosciences subsidia
Strategic Partnership Boosts Poseida Therapeutics' Solid Tumor Treatment Capabilities and Underpins Buy Rating
Express News | Poseida Therapeutics Shares Are Trading Higher After the Company Announced That It Entered Into a Research Collaboration and License Agreement With Astellas to Develop Novel ConvertibleCAR Programs
Express News | Poseida Therapeutics Inc - Is Eligible for up to Low Double Digit Tiered Royalties as a Percentage of Net Sales Under Deal
Express News | Poseida Therapeutics - to Receive US $50 Mln Upfront Plus Potential Development,Sales Milestones, Contingency Payments of up to US $550 Mln in Total
Express News | Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price target.
Poseida Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 890.1% HC Wainwright & Co. → $20 Reiterates Buy → Buy 03/08/2024 890.1% HC Wainwright & Co. → $
Express News | Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27TH Annual Meeting
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE), Poseida Therapeutics (PSTX) and Align Tech (ALGN)
No Data